Injected insulin halts the Krebs cycle, blocks protein and DNA synthesis, starves the brain of glucose and causes seizures and blood clots.
Original statement
يقول الدكتور ضياء العوضي إن الأنسولين ... وإن حقنه يوقف دورة كريبس فيعيق تصنيع البروتينات والحمض النووي ويسبب تشنجات وجلطات.
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Injected insulin halts the Krebs cycle, blocks protein and DNA synthesis, starves the brain of glucose and causes seizures and blood clots.
Origin
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/insulin-injections/
- Attribution uncertainty
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase (partial). Krebs-cycle blockade (9-ai4_JBX6c) and clots in insulin users (5H-C06AT55Q) are found as close paraphrases. 'Blocks protein and DNA synthesis', 'starves the brain of glucose' and 'seizures' were not checked verbatim.
- Claimed mechanism
Insulin 'freezes' cells and stops the Krebs (citric acid) cycle so glucose cannot be used.
- Claimed health effect
Impaired protein/DNA synthesis, seizures, clots, brain glucose deprivation.
- Population concerned
People treated with insulin
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- المفاهيم المضللة عن الإنسولين ومغالطات شائعه حول الإنسولين #ضياء_العوضي (Open source)
- Published
- 17 April 2026
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
عدم القدره على اصلاح الاعطال عارف ليه عشان ما عنديش انتي اوكسدنت اما تحقن انسولين تعطل الكريبس الكريبس اتعطلت الكريبس اتعطلت اتعطل معاها انتاج الاي تي بي الاكس فوسفوريشن فالجسم يتلج ما عندكش انتاج حراره ولا انتاج
Injecting insulin disables the Krebs cycle and with it ATP production (oxidative phosphorylation), so the body 'freezes' and cannot produce heat.
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live! الكورتيزون حياتك (Open source)
- Published
- 17 October 2025
- Timestamp
- 1:44:41 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
مش صدفه مش صدفه اللي بياخد انسولين دايما كل سنه يجي له جلطه في الشران بتاع عينيه ولا جلطه في شيران التاجي بالصدفه بالصدفه يضيق عليك وانت بتاخد
It is not a coincidence, not a coincidence that whoever takes insulin gets a clot every year in the artery of his eyes or in the coronary arteries - by coincidence? It narrows on you while you are taking [insulin].
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- الذبحة الصدرية ؟! (Open source)
- Published
- 3 February 2025
- Timestamp
- 1:13:35 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Close paraphrase of the clots part.
Scientific assessment
False – The statement contradicts the robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Insulin stops the Krebs cycle, blocks protein and DNA synthesis and causes seizures and clots.
2. What is demonstrably correct?
An overdose of insulin causes hypoglycaemia, which can cause seizures and loss of consciousness. Severe hypoglycaemia was more frequent with intensive treatment in ACCORD, ADVANCE, VADT, UKPDS and DCCT (A-INS-01, I-INS-01, A-INS-03, A-INS-16, I-INS-03) and was associated with later vascular events and death (A-INS-14, A-INS-15), although in ADVANCE it occurred mainly under sulfonylurea-based therapy in people not on long-term insulin (A-INS-15).
3. What is wrong or exaggerated?
Insulin does not stop the Krebs cycle; it increases glucose uptake into muscle and fat (via GLUT4) and promotes glucose oxidation and storage. Insulin is anabolic: it stimulates protein synthesis and inhibits protein breakdown; insulin deficiency (type 1 diabetes, ketoacidosis) causes muscle wasting. No study presented by the archive shows insulin causes clots at therapeutic doses. The hypoglycaemia studies the archive cites contain no evidence on the Krebs cycle, protein or DNA synthesis or clots: in ACCORD, of 431 adjudicable deaths hypoglycaemia was definitely involved in 1 and probably in 3, and excess hypoglycaemia explained only about 5 of 57 excess deaths in the intensive arm (A-INS-14); in ADVANCE associations were non-specific (also with respiratory, digestive and skin disease), without a dose-response, and the authors judged hypoglycaemia as likely a marker of vulnerability as a cause (A-INS-15).
4. What remains unclear?
Whether severe hypoglycaemia itself causes cardiovascular events or mainly marks frail patients is unresolved (A-INS-15).
5. Which studies support it?
None for the mechanistic claims. Mixed: A-INS-14, A-INS-15 (support only the kernel that severe hypoglycaemia under glucose-lowering treatment occurs and marks higher risk).
6. Which studies contradict it?
Standard biochemistry; I-INS-07 and I-INS-08 (insulin is the cornerstone of treating ketoacidosis, a state of insulin deficiency with catabolism); I-INS-03; A-INS-14 and A-INS-15 (hypoglycaemia mostly a marker, rarely a direct cause of death).
7. What applies to Germany and Europe?
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
The real risk of insulin is hypoglycaemia, which is managed by appropriate targets, dosing, glucose monitoring and education, not by stopping insulin.
Assessment details
- Rationale for certainty of evidence
Textbook physiology: insulin stimulates glucose uptake and oxidation in muscle and fat and is an anabolic hormone that promotes protein synthesis; no evidence that insulin stops the Krebs cycle. The only correct kernel (seizures from insulin-induced hypoglycaemia) is well documented.
- Source quality
Archive paraphrase plus own words in machine transcript.
- Regional transferability
Universal physiology.
- Individual exceptions
Hypoglycaemia (too much insulin relative to need) can cause confusion, seizures and, rarely, death; this is a dosing problem, not a property of insulin at physiological levels.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Insulin does not stop the cell's energy engine. It helps muscle and fat take up sugar and it helps build protein. The real danger of insulin is a dose that is too high, which makes blood sugar fall too low; this can cause confusion and seizures. That risk is handled by careful dosing and checking blood sugar.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (3)
-
International guideline on diabetic ketoacidosis
Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032Guideline / position statementindependent cross-checkfull text checked★ key studyInsulin, fluids and potassium are the core treatment; with this, fewer than 1% of adults die.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diagnosis and management of DKA and HHS in adults
- How was the study done?
International consensus report based on systematic examination of literature since 2009 (ADA, EASD, JBDS, AACE, DTS)
- How many people, animals or samples were studied?
not applicable; Adults with diabetes
- What was actually found?
Insulin is the cornerstone; glucocorticoids worsen hyperglycaemia.
- How large was the observed effect?
Mortality <1% with treatment
- What do the results mean in everyday life?
Ketoacidosis needs hospital treatment with insulin.
- What are the study's limitations?
Consensus, not trial
- What does it say about Elawady's specific claim?
Directly contradicts C-INS-08; supports danger in C-FAST-03; contradicts C-INS-07, C-INS-10.
- Do the results apply to Germany and Europe?
EASD and JBDS (UK) co-authored; directly applicable.
- What can explicitly not be concluded from this study?
Outcomes of untreated DKA quantitatively.
-
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1Narrative reviewindependent cross-checkfull text checkedDKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Epidemiology, pathogenesis, diagnosis and management of DKA
- How was the study done?
Narrative expert review (Nature Reviews Disease Primers)
- How many people, animals or samples were studied?
not applicable; Adults and children with diabetes
- What was actually found?
DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
DKA is an emergency.
- What are the study's limitations?
Narrative expert review without systematic methods; one author has research support from insulin makers.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
International.
- What can explicitly not be concluded from this study?
Quantitative estimates.
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401Randomised controlled trialindependent cross-checkabstract only checked★ key studyIntensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- How was the study done?
Multicentre RCT (DCCT)
- How many people, animals or samples were studied?
1,441; Insulin-dependent (type 1) diabetes
- What was actually found?
Large reductions in all microvascular complications.
- How large was the observed effect?
Retinopathy -76%
- What do the results mean in everyday life?
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- What are the study's limitations?
Open-label; Selected young population
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).
- Do the results apply to Germany and Europe?
North American; universally accepted.
- What can explicitly not be concluded from this study?
Effects in type 2 diabetes directly.
No study in this group is marked as key.
Studies with mixed or unclear results (2)
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909Cohort studycited by the Tayebat archivefull text checked★ key studyPeople who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link between severe hypoglycaemia and mortality in ACCORD
- How was the study done?
Retrospective epidemiological analysis within an RCT (ACCORD)
- How many people, animals or samples were studied?
10,194; ACCORD participants with hypoglycaemia assessment
- What was actually found?
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- How large was the observed effect?
aHR 1.41 (1.03-1.93) intensive arm
- What do the results mean in everyday life?
Severe hypoglycaemia is a danger sign to avoid.
- What are the study's limitations?
Post-hoc observational analysis; Confounding by frailty
- What does it say about Elawady's specific claim?
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795Cohort studycited by the Tayebat archivefull text checkedSevere low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Severe hypoglycaemia and vascular events/death
- How was the study done?
Post-hoc cohort analysis of an RCT (ADVANCE)
- How many people, animals or samples were studied?
11,140; ADVANCE participants with type 2 diabetes
- What was actually found?
aHR 2.69 death.
- How large was the observed effect?
aHR 2.69 (1.97-3.67)
- What do the results mean in everyday life?
Avoid severe hypoglycaemia.
- What are the study's limitations?
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Regional context
Germany / EU
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
False The Krebs-cycle and DNA claims are false; the only true part is that insulin overdose can cause dangerous hypoglycaemia.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.. Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032
- Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795